Summary: Pomegranate juice appears to have neuroprotective effects in pregnancies marked by intrauterine growth restriction. Researchers found pomegranate juice reduced the risk of brain injury in infants with IUGR, especially when pregnant women drank it during the third trimester.
Source: Brigham and Women’s Hospital
Intrauterine growth restriction (IUGR) is common and concerning, but few therapeutic options exist for pregnant mothers who receive this diagnosis. IUGR is a condition in which a baby in the womb is measuring small for its gestational age, often because of issues with the placenta, resulting in compromised or insufficient transfer of oxygen and nutrients to the growing fetus. The developing fetal brain is particularly vulnerable to these effects.
One out of every 10 babies is diagnosed with IUGR, and infants with IUGR are at increased risk of death and neurodevelopmental impairment. Recent research on polyphenol-rich pomegranate juice has suggested that it may help protect the brain from injury.
In an exploratory, randomized, controlled clinical trial, supported by philanthropic funding and a gift from POM Wonderful, the largest grower and producer of fresh pomegranates and pomegranate juice in the United States, investigators at Brigham and Women’s Hospital enrolled pregnant mothers whose infants were diagnosed with IUGR.
The team found evidence that drinking pomegranate juice daily may reduce risk of brain injury in IUGR infants, especially during the third trimester when the infant brain may be particularly vulnerable.
Findings are published in Scientific Reports.
“There are dietary factors that may influence neuroprotection, especially in high-risk settings such as during labor and delivery,” said co-author Terrie Inder, MBCHB, chair of the Department of Pediatric Newborn Medicine at the Brigham.
“We were intrigued by findings from preclinical research suggesting that polyphenols, which are found at high concentrations in pomegranate juice, might be highly protective. Our clinical trial provides the most promising evidence to date that polyphenols may provide protection from risk of brain injury in IUGR infants.”
“While exploratory, our results are promising and suggest that being able to intervene before birth may aid in protecting the newborn brain from the devastating effects of brain injury,” said corresponding author Lillian G. Matthews, PhD, a neuroscientist at Monash Biomedical Imaging and Turner Institute for Brain and Mental Health in Australia. Prior to joining Monash, Matthews was at Harvard Medical School and the Brigham in the Department of Pediatric and Newborn Medicine, where she maintains a current affiliation.
Polyphenols are part of a class of antioxidants found in certain foods and beverages, including almonds, berries, red wine and teas. Pomegranate juice is a particularly rich source of these molecules. Polyphenols are known to cross the blood-brain barrier, and studies in animal models have demonstrated protective effects against neurodegenerative diseases.
For their clinical trial, Inder and colleagues recruited 99 pregnant mothers at the Brigham. The participants were randomly assigned to consume either 8 ounces of pomegranate juice or a polyphenol-free beverage matched for color, taste and calorie-count. Participants drank the juice daily from the time of enrollment until delivery.
The team performed fetal MRI measurements on approximately half of the participants prior to mothers starting the juice regimen and found no evidence of fetal brain injury at that time.
After delivery, neonatal MRI measurements showed that infants whose mothers consumed pomegranate juice were less likely to have brain injury compared to those randomized to placebo. Infants had lower risk of cortical grey matter injury and white matter injury.
The team also found no evidence of ductal constriction, a potential safety concern.
Given the exploratory nature of the study and its limited size, the authors caution that larger controlled trials are needed. The team also plans to continue studying infants enrolled in their study over the next 2-3 years to assess the infants’ neurodevelopmental outcome.
“Our neurodevelopmental follow-up studies are ongoing, and we encourage other investigators studying high-risk infant populations to consider the influence of polyphenols for neuroprotection,” said Inder. “My dream is that we will one day be able to offer women a way to help shield their infant’s brain from potential injury. In the meantime, we’ll continue to follow participants to provide further insight into the potential clinical implications of prenatal pomegranate juice.”
Funding: This work was supported by the Brigham and Women’s Hospital Program for Interdisciplinary Neuroscience Award and a gift to Brigham and Women’s Hospital from POM Wonderful, Los Angeles.
About this brain development research news
Source: Brigham and Women’s Hospital
Contact: Elaine St Peter – Brigham and Women’s Hospital
Image: The image is in the public domain
Original Research: Open access.
“A randomized controlled trial investigating the impact of maternal dietary supplementation with pomegranate juice on brain injury in infants with IUGR” by Madeline M. Ross, Sara Cherkerzian, Nicole D. Mikulis, Daria Turner, Julian Robinson, Terrie E. Inder & Lillian G. Matthews. Scientific Reports
A randomized controlled trial investigating the impact of maternal dietary supplementation with pomegranate juice on brain injury in infants with IUGR
Animal studies have demonstrated the therapeutic potential of polyphenol-rich pomegranate juice.
We recently reported altered white matter microstructure and functional connectivity in the infant brain following in utero pomegranate juice exposure in pregnancies with intrauterine growth restriction (IUGR). This double-blind exploratory randomized controlled trial further investigates the impact of maternal pomegranate juice intake on brain structure and injury in a second cohort of IUGR pregnancies diagnosed at 24–34 weeks’ gestation.
Ninety-nine mothers and their eligible fetuses (n = 103) were recruited from Brigham and Women’s Hospital and randomly assigned to 8 oz pomegranate (n = 56) or placebo (n = 47) juice to be consumed daily from enrollment to delivery. A subset of participants underwent fetal echocardiogram after 2 weeks on juice with no evidence of ductal constriction. 57 infants (n = 26 pomegranate, n = 31 placebo) underwent term-equivalent MRI for assessment of brain injury, volumes and white matter diffusion.
No significant group differences were found in brain volumes or white matter microstructure; however, infants whose mothers consumed pomegranate juice demonstrated lower risk for brain injury, including any white or cortical grey matter injury compared to placebo.
These preliminary findings suggest pomegranate juice may be a safe in utero neuroprotectant in pregnancies with known IUGR warranting continued investigation.
Clinical trial registration: NCT04394910, https://clinicaltrials.gov/ct2/show/NCT04394910, Registered May 20, 2020, initial participant enrollment January 16, 2016.